Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer

Table 1 Patient characteristics n (%)

	Surgery only	FOLFOX6		XELOX		P value1
	(n = 634)	(n = 48)	P value	(n = 214)	P value
Age (yr)
Mean ± SD	58.9 ± 12.5	51.2 ± 13.2	< 0.001	55.2 ± 11.4	< 0.001	0.051
Median	60	52		57
Tumor location, whole stomach	23 (3.6)	5 (10.4)		7 (3.3)		0.124
Upper	192 (30.3)	11 (22.9)		55 (25.7)
Middle	148 (23.3)	16 (33.3)		61 (28.5)
Lower	235 (37.1)	14 (29.2)		87 (40.7)
Remnant stomach	36 (5.7)	2 (4.2)		4 (1.9)
Macroscopic Borrmann type			0.035		0.014	0.064
I	39 (6.2)	0 (0.0)		13 (6.1)
II	171 (27)	7 (14.6)		39 (18.2)
III	333 (52.5)	30 (62.5)		138 (64.5)
IV and V	91 (14.4)	11 (22.9)		24 (11.2)
Histological type			0.219		0.013	0.919
Differentiated	245 (38.6)	14 (29.2)		64 (29.9)
Undifferentiated	389 (61.4)	34 (70.8)		150 (70.1)
Pathological T category			< 0.001		< 0.001	0.087
T1 and 2	117 (18.5)	0 (0.0)		9 (4.2)
T3	73 (11.5)	1 (2.1)		23 (10.7)
T4a	342 (53.9)	41 (85.4)		152 (71)
T4b	102 (16.1)	6 (12.5)		30 (14)
Retrieved node
Mean ± SD	26.4 ± 15.9	32.1 ± 19.2	0.019	29.7 ± 14.5	0.004	0.339
Median (range)	24 (0-102)	31 (0-89)		27 (1-91)
Pathological N category			0.005		< 0.001	0.085
N0	268 (42.3)	8 (16.7)		41 (19.2)
N1	91 (14.4)	7 (14.6)		43 (20.1)
N2	108 (17)	12 (25)		52 (24.3)
N3a	89 (14)	9 (18.8)		56 (26.2)
N3b	78 (12.3)	12 (25)		22 (10.3)

¹Capecitabine and oxaliplatin (XELOX) group vs 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) group.